Universal Health Services’ fair value estimate has inched higher to about $249.94 per share, reflecting slightly stronger long term revenue assumptions and a largely unchanged risk backdrop. The market’s narrative is being reshaped by more constructive Street research following robust Q3 results, even as policy and execution risks keep debate around valuation balanced. Stay tuned to see how investors can monitor these shifting analyst views and track the evolving story around UHS from here.

Stay updated as the Fair Value for Universal Health Services shifts by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Universal Health Services.

???? Bullish Takeaways

Several firms have turned more constructive after strong Q3 execution, with Mizuho lifting its target to $267 and Raymond James upgrading UHS to Outperform with a $270 target, citing better than expected results and attractive valuation.

Barclays and Wells Fargo, both Overweight, raised targets to $263 and $259 respectively, pointing to stronger EBITDA, improved operational execution and solid underlying demand trends as drivers of higher long term earnings power.

Analysts reward UHS for clearer guidance and consistent delivery against expectations, with multiple firms extending or rolling their models out to 2027 and applying higher multiples where they see durable core acute growth.

Even Morgan Stanley, at Equal Weight with a higher $233 target, highlights “undemanding” valuation and the potential for a re rating if admissions, particularly in behavioral health, continue to improve.

???? Bearish Takeaways

BofA, despite raising its target to $190, keeps an Underperform rating, arguing that UHS has above average exposure to policy changes and that core results remain weak relative to perceived risks.

Wells Fargo explicitly bakes in a higher probability that enhanced exchange subsidies expire, while other firms flag that some of the upside from better execution and cost control may already be reflected in the recent re rating.

Across the more cautious research, the message is that further upside in the stock will likely require sustained admissions growth, particularly in behavioral, and continued flawless execution against 2025 2027 EBITDA targets.

Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there's more to the story. Head to the Simply Wall St Community to discover more perspectives or begin writing your own Narrative!

Raised full year 2025 consolidated net revenue guidance to a range of $17.306 billion to $17.445 billion, supported by stronger operating trends and a new Medicaid supplemental payment program in Washington, D.C.

Expanded its share repurchase authorization by $1.5 billion on October 27, 2025. This brought total approved buyback capacity to $7.6 billion and reinforced management’s focus on shareholder returns.

Repurchased 1,314,696 shares, or 2.07% of shares outstanding, for $234.32 million between July 1 and September 30, 2025. This lifted cumulative buybacks under the long running program to 43,123,370 shares, or 53.51%, for $5.84 billion.

Removed from the FTSE All World Index. This change may create a technical headwind for index linked flows and could modestly affect trading liquidity and ownership mix.

Fair value estimate has risen slightly, moving from approximately $248.71 to about $249.94 per share, reflecting modestly higher long term assumptions.

Discount rate is effectively unchanged, edging down immaterially from 6.956% to 6.956%, indicating a stable risk and return framework.

Revenue growth outlook remains essentially flat, with the long term annual growth rate holding at roughly 4.25%.

Net profit margin projection is effectively unchanged, ticking up only fractionally from about 8.33% to 8.33% on a percentage basis.

Future P/E multiple has risen slightly, increasing from about 10.44x to approximately 10.49x, modestly supporting a higher valuation.

Narratives on Simply Wall St connect the story behind a company with the numbers investors care about, combining your view on future revenue, earnings, and margins with a fair value estimate. By linking UHS’s business outlook to a dynamic forecast and valuation, Narratives make it easy to see when Fair Value and the current price diverge, and they update automatically as new news or earnings arrive within the Community page used by millions of investors.

Head over to the Simply Wall St Community and follow the Narrative on Universal Health Services to stay on top of the evolving story:

How outpatient behavioral growth and new hospitals could support long term revenue, margin expansion, and UHS’s fair value.

Whether regulatory and reimbursement risks might cap upside, even if demand and execution remain solid.

How updated analyst forecasts and shifting P/E assumptions change the gap between Fair Value and today’s share price.

Read the full Universal Health Services Narrative on Simply Wall St to see how this thesis translates into forecasts, valuation, and potential returns.

Curious how numbers become stories that shape markets? Explore Community Narratives

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include UHS.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com